Terns Pharmaceuticals Inc (STU:430)

€ 5.6 0.05 (0.9%) Market Cap: 470.26 Mil Enterprise Value: 113.82 Mil PE Ratio: 0 PB Ratio: 1.34 GF Score: 41/100

Terns Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2024
Terns Pharmaceuticals Inc at UBS BioPharma Conference Transcript
Nov 08, 2023
Terns Pharmaceuticals Inc at H.C. Wainwright & Co LLC 7th Annual NASH Investor Conference (Virtual) Transcript
Oct 24, 2023
Terns Pharmaceuticals Inc at HC Wainwright Investment Conference - New York Transcript
Sep 11, 2023
Terns Pharmaceuticals Inc Obesity Franchise Webinar Transcript
Jun 29, 2023
Terns Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript
Jun 13, 2023
Terns Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Jun 08, 2023
Terns Pharmaceuticals Inc at TD Cowen Oncology Innovation Summit (Virtual) Transcript
May 31, 2023
Terns Pharmaceuticals Inc at JMP Securities Life Sciences Conference Transcript
May 15, 2023
Terns Pharmaceuticals Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 14, 2023
Terns Pharmaceuticals Inc at Guggenheim Healthcare Talks Oncology Day Transcript
Feb 09, 2023
Terns Pharmaceuticals Inc at B Riley Securities Oncology Conference (Virtual) Transcript
Jan 18, 2023
Terns Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Jan 12, 2023
Terns Pharmaceuticals Inc at JMP Securities Hematology Oncology Summit (Virtual) Transcript
Dec 06, 2022
Terns Pharmaceuticals Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript
Nov 30, 2022
Terns Pharmaceuticals Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript
Oct 17, 2022
Terns Pharmaceuticals Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 14, 2022
Terns Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 11, 2022
Terns Pharmaceuticals Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript
Oct 12, 2021
Terns Pharmaceuticals Inc at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) Transcript
Sep 20, 2021

Terns Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

Jan 10, 2024 / 09:30PM GMT

Release Date Price: €5.54 (-8.73%)

Transcript

Eric Joseph JPMorgan;Analyst

Good afternoon. I'm Eric Joseph, senior biotech analyst with JPMorgan. And our next presenting company is Terns Pharmaceuticals. Presenting on behalf of the company is President and Head of R&D, Erin Quirk.

(Conference Instructions) So with that, Erin, thanks for joining us.

Erin Quirk Terns Pharmaceuticals

Inc. - President & Head of Research & Development

Great. Eric, thanks so much for the introduction. And thanks to you and the entire JPMorgan team for the opportunity to be at the conference and present today. It's always great to be at JPMorgan, and we really appreciate the support and invitation.

So I'll give you an overview of Terns today and the really exciting outlook we have for 2024. As always, I'd invite you to go to our website to look at disclaimers regarding forward-looking statements.

So Terns is a biotech company. We're developing small molecule medicines with clinically validated mechanisms of action to address important needs focused currently on oncology and

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.